Why the study?
Does high-dose aspirin compared to dihydroergotamine-heparin prevent thromboembolism in patients over 50 years of age undergoing total hip replacement?
Does high-dose aspirin compared to dihydroergotamine-heparin prevent thromboembolism in patients over 50 years of age undergoing total hip replacement?
In patients undergoing total hip replacement, high-dose aspirin appeared to prevent thromboembolism effectively only in men compared to dihydroergotamine-heparin.
Answers are grounded in this paper and cite their sources.
Aspirin was associated with higher thromboembolism rates than dihydroergotamine-heparin in women after hip replacement; hypothesis-generating for sex-specific effects, needs prospective confirmation.
In a prospective and controlled study, we compared the prophylactic effect of high-dose acetylsalicylic acid (ASA) and dihydroergotamine-heparin (DHEH) in 82 patients over 50 years of age undergoing total hip replacement. The patients were screened by pulmonary scan and 125I fibrinogen uptake. Phlebography was done if the 125 I fibrinogen test was positive. According to our criteria, thromboembolism developed in 9 of 40 receiving ASA and in 5 of 42 patients receiving DHEH. The effect of ASA was limited to men; in 16 men on this therapy, none had thromboembolism versus 9 of 24 women. Twenty-two patients showed wound hematomas, but none needed surgical intervention.
No takes yet. Share an insight, caveat, or question.
Josefsson et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: